{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:30:28Z","timestamp":1785731428767,"version":"3.56.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CIHR Postdoctoral Fellowship","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Fonds de recherche du Qu\u00e9bec Research Scholar Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000026","name":"US National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["U01DA038886"],"award-info":[{"award-number":["U01DA038886"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"US National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["U01DA021525"],"award-info":[{"award-number":["U01DA021525"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"name":"St. Paul\u2019s Hospital Chair in Substance Use Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research Scholar Award","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015150","name":"St. Michael\u2019s Hospital Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COVID-19 pandemic had a disproportionate impact on the health and wellbeing of people who use drugs (PWUD) in Canada. However less is known about jurisdictional commonalities and differences in COVID-19 exposure and impacts of pandemic-related restrictions on competing health and social risks among PWUD living in large urban centres.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between May 2020 and March 2021, leveraging infrastructure from ongoing cohorts of PWUD, we surveyed 1,025 participants from Vancouver (<jats:italic>n<\/jats:italic>\u2009=\u2009640), Toronto (<jats:italic>n<\/jats:italic>\u2009=\u2009158), and Montreal (<jats:italic>n<\/jats:italic>\u2009=\u2009227), Canada to describe the impacts of pandemic-related restrictions on basic, health, and harm reduction needs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among participants, awareness of COVID-19 protective measures was high; however, between 10 and 24% of participants in each city-specific sample reported being unable to self-isolate. Overall, 3\u201319% of participants reported experiencing homelessness after the onset of the pandemic, while 20\u201341% reported that they went hungry more often than usual. Furthermore, 8\u201333% of participants reported experiencing an overdose during the pandemic, though most indicated no change in overdose frequency compared the pre-pandemic period. Most participants receiving opioid agonist therapy in the past six months reported treatment continuity during the pandemic (87\u201393%), however, 32% and 22% of participants in Toronto and Montreal reported missing doses due to service disruptions. There were some reports of difficulty accessing supervised consumption sites in all three sites, and drug checking services in Vancouver.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Findings suggest PWUD in Canada experienced difficulties meeting essential needs and accessing some harm reduction services during the COVID-19 pandemic. These findings can inform preparedness planning for future public health emergencies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-00996-x","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:02:04Z","timestamp":1715821324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The impact of the COVID-19 pandemic on people who use drugs in three Canadian cities: a cross-sectional analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Sanjana","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Zolopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"H\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanor","family":"Minoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indhu","family":"Rammohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Yin","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanna","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-J","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kora","family":"DeBeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayden","family":"Scheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"996_CR1","unstructured":"Public Health Agency of Canada. Minimizing the risk of exposure to COVID-19 in Canada Order. Canada Gazette Part I 154; 2020. [http:\/\/gazette.gc.ca\/rp-pr\/p1\/2020\/2020-04-04\/pdf\/g1-15414.pdf ]"},{"key":"996_CR2","unstructured":"Government of Canada. Coronavirus disease (COVID-19): Canada\u2019s response [updated March 13 2020]. 2020 [https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/canadas-reponse.html?topic=tilelink]"},{"key":"996_CR3","unstructured":"Government of Quebec. Concerning the declaration of the public health emergency under section 119 of the Public Health Act and certain measures to protect the health of the population; 2020."},{"key":"996_CR4","unstructured":"Government of British Columbia. Province declares state of emergency to support COVID-19 response; 2020. [https:\/\/news.gov.bc.ca\/21826]"},{"issue":"2","key":"996_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/10826084.2016.1267225","volume":"53","author":"H Matusow","year":"2018","unstructured":"Matusow H, Benoit E, Elliott L, Dunlap E, Rosenblum A. Challenges to Opioid Treatment Programs after Hurricane Sandy: patient and provider perspectives on Preparation, Impact, and recovery. Subst Use Misuse. 2018;53(2):206\u201319.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"996_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/jurban\/79.3.392","volume":"79","author":"L Weiss","year":"2002","unstructured":"Weiss L, Fabri A, McCoy K, Coffin P, Netherland J, Finkelstein R. A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center. J Urban Health. 2002;79(3):392\u2013403.","journal-title":"J Urban Health"},{"issue":"1","key":"996_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1940-0640-9-3","volume":"9","author":"B Tofighi","year":"2014","unstructured":"Tofighi B, Grossman E, Williams AR, Biary R, Rotrosen J, Lee JD. Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addict Sci Clin Pract. 2014;9(1):3.","journal-title":"Addict Sci Clin Pract"},{"key":"996_CR8","doi-asserted-by":"publisher","first-page":"103127","DOI":"10.1016\/j.drugpo.2021.103127","volume":"92","author":"C Zolopa","year":"2021","unstructured":"Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts of big events on risks, harms, and service delivery among people who use drugs: implications for responding to COVID-19. Int J Drug Policy. 2021;92:103127.","journal-title":"Int J Drug Policy"},{"key":"996_CR9","unstructured":"Government of Canada. Modelling opioid-related deaths during the COVID-19 outbreak 2021. [https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research\/modelling-opioid-overdose-deaths-covid-19.html]"},{"issue":"1","key":"996_CR10","first-page":"157","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157\u201360.","journal-title":"Acta Biomed"},{"key":"996_CR11","volume-title":"Preliminary patterns in circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic","author":"Ontario Drug Policy Research Network; Office of the Chief Coroner for Ontario\/Ontario Forensic Pathology Service; Ontario Agency for Health Protection and Promotion (Public Health Ontario); Centre on Drug Policy Evaluation.","year":"2020","unstructured":"Ontario Drug Policy Research Network; Office of the Chief Coroner for Ontario\/Ontario Forensic Pathology Service; Ontario Agency for Health Protection and Promotion (Public Health Ontario); Centre on Drug Policy Evaluation. Preliminary patterns in circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Toronto, ON: Ontario Drug Policy Research Network; 2020."},{"issue":"4","key":"996_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/dar.13424","volume":"41","author":"H Palis","year":"2022","unstructured":"Palis H, B\u00e9lair MA, Hu K, Tu A, Buxton J, Slaunwhite A. Overdose deaths and the COVID-19 pandemic in British Columbia, Canada. Drug Alcohol Rev. 2022;41(4):912\u20137.","journal-title":"Drug Alcohol Rev"},{"key":"996_CR13","doi-asserted-by":"crossref","unstructured":"Imtiaz S, Nafeh F, Russell C, Ali F, Elton-Marshall T, Rehm J. The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data. J Subst Abuse Treat. 2021;16(1):87.","DOI":"10.1186\/s13011-021-00423-5"},{"issue":"1","key":"996_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-022-00653-1","volume":"19","author":"FN Conway","year":"2022","unstructured":"Conway FN, Samora J, Brinkley K, Jeong H, Clinton N, Claborn KR. Impact of COVID-19 among people who use drugs: a qualitative study with harm reduction workers and people who use drugs. Harm Reduct J. 2022;19(1):72.","journal-title":"Harm Reduct J"},{"issue":"1","key":"996_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12954-023-00741-w","volume":"20","author":"L Frueh","year":"2023","unstructured":"Frueh L, Collins AB, Newman R, Barnett NP, Rich JD, Clark MA, et al. Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation. Harm Reduct J. 2023;20(1):14.","journal-title":"Harm Reduct J"},{"key":"996_CR16","doi-asserted-by":"publisher","first-page":"108374","DOI":"10.1016\/j.jsat.2021.108374","volume":"129","author":"C Russell","year":"2021","unstructured":"Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021;129:108374.","journal-title":"J Subst Abuse Treat"},{"key":"996_CR17","unstructured":"Government of Canada. Measuring the impact of the opioid overdose epidemic on life expectancy at birth in Canada; 2020. [https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research\/measuring-impact-on-life-expectancy.html]"},{"key":"996_CR18","unstructured":"Government of Canada. Modelling opioid-related deaths during the overdose crisis; 2023. [https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/data-surveillance-research\/modelling.html]"},{"key":"996_CR19","unstructured":"Health Canada, Public Health Agency of Canada, and U.S. Department of Health and Human Services. Canada-U.S. Joint White Paper: Substance Use and Harms during the COVID-19 pandemic and approaches to Federal Surveillance and Response. Ottawa, Ontario; 2022. [https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canada-us-white-paper-substance-use-harms-during-covid-19-pandemic-approaches-federal-surveillance-response.html]"},{"key":"996_CR20","volume-title":"The invisible siege: the rise of coronaviruses and the search for a cure. Doughten EbK","author":"D Werb","year":"2022","unstructured":"Werb D. The invisible siege: the rise of coronaviruses and the search for a cure. Edited by K Doughten. New York: Crown\/Penguin Random House; 2022."},{"issue":"1","key":"996_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12889-023-15474-5","volume":"23","author":"A Foreman-Mackey","year":"2023","unstructured":"Foreman-Mackey A, Xavier J, Corser J, Fleury M, Lock K, Mehta A, et al. It\u2019s just a perfect storm: exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances. BMC Public Health. 2023;23(1):640.","journal-title":"BMC Public Health"},{"key":"996_CR22","doi-asserted-by":"crossref","unstructured":"Gubskaya E, Kennedy MC, Hayashi K, Cui Z, Milloy MJ, Kerr T. The impact of the COVID-19 pandemic on access to supervised consumption programs. J Subst Abuse Treat. 2023;18(1):16.","DOI":"10.1186\/s13011-023-00521-6"},{"issue":"1","key":"996_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12954-022-00620-w","volume":"19","author":"N Minoyan","year":"2022","unstructured":"Minoyan N, H\u00f8j SB, Zolopa C, Vlad D, Bruneau J, Larney S. Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada. Harm Reduct J. 2022;19(1):38.","journal-title":"Harm Reduct J"},{"issue":"9","key":"996_CR24","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1017\/S1368980023001234","volume":"26","author":"T Singh Kelsall","year":"2023","unstructured":"Singh Kelsall T, DeBeck K, Grant C, Gorbach P, Milloy MJ, Hayashi K. Food insecurity during the COVID-19 pandemic who use drugs in Vancouver, Canada. Public Health Nutr. 2023;26(9):1878\u201386.","journal-title":"Public Health Nutr"},{"key":"996_CR25","doi-asserted-by":"publisher","first-page":"103237","DOI":"10.1016\/j.drugpo.2021.103237","volume":"93","author":"F Ali","year":"2021","unstructured":"Ali F, Russell C, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada. Int J Drug Policy. 2021;93:103237.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"996_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12954-017-0177-7","volume":"14","author":"E Hyshka","year":"2017","unstructured":"Hyshka E, Anderson-Baron J, Karekezi K, Belle-Isle L, Elliott R, Pauly B, et al. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks. Harm Reduct J. 2017;14(1):50.","journal-title":"Harm Reduct J"},{"key":"996_CR27","unstructured":"Wadhwani A. COVID-19: Here\u2019s a phase-by-phase look at how B.C. hopes to re-open parts of society. Victoria News; 2020. [https:\/\/www.vicnews.com\/news\/covid-19-heres-a-phase-by-phase-look-at-how-b-c-hopes-to-re-open-parts-of-society-71273]"},{"key":"996_CR28","unstructured":"Government of British Columbia. B.C. Shifts to step 3 of restart plan [press release]. Victoria: Office of the Premier; 2021."},{"key":"996_CR29","unstructured":"City of Vancouver. COVID-19 (Coronavirus): community support; 2023. [https:\/\/vancouver.ca\/people-programs\/community-resilience.aspx#centres]"},{"key":"996_CR30","volume-title":"Significantly enhanced measures will help Contain Spread of COVID-19. [press release]","author":"Ontario Enacts Declaration of Emergency to Protect the Public","year":"2020","unstructured":"Ontario Enacts Declaration of Emergency to Protect the Public. Significantly enhanced measures will help Contain Spread of COVID-19. [press release]. Toronto: Queen\u2019s Printer for Ontario; 2020. [https:\/\/news.ontario.ca\/en\/release\/56356\/ontario-enacts-declaration-of-emergency-to-protect-the-public]"},{"key":"996_CR31","volume-title":"COVID-19 isolation and Recovery sites evaluation: a MARCOS Report","author":"M Firestone","year":"2021","unstructured":"Firestone M, Bayoumi AM, Steer L, Khoee K, Akaehomhen A, Lee Soh B, et al. COVID-19 isolation and Recovery sites evaluation: A MARCOS Report. Toronto, Ontario: MAP Centre for Urban Health Solutions, St. Michael\u2019s Hospital; 2021."},{"key":"996_CR32","unstructured":"Pagliaro J. City\u2019s busiest supervised injection site to reopen after month-long closure over COVID-19. The Toronto Star; 2020. [https:\/\/www.thestar.com\/news\/gta\/city-hall\/city-s-busiest-supervised-injection-site-to-reopen-after-month-long-closure-over-covid-19\/article_8967ab57-d064-5876-aeff-9032e3e11fe9.html]"},{"key":"996_CR33","unstructured":"Jeffords S. Opioid crisis worsens during pandemic as services for drug users scale back. CP24; 2020 April 30. [https:\/\/www.cp24.com\/news\/opioid-crisis-worsens-during-pandemic-as-services-for-drug-users-scale-back-1.4919407]"},{"key":"996_CR34","unstructured":"Montpetit J, Stevenson V. COVID-19 in Quebec: travel restrictions to be lifted in most regions over month of May. CBC News; 2020. [https:\/\/www.cbc.ca\/news\/canada\/montreal\/covid-19-quebec-april-29-1.5548806]"},{"key":"996_CR35","unstructured":"Initiatives of the City of Montreal during the COVID-19 crisis. Intercultural Cities Newsroom - Council of Europe; 2023. [https:\/\/www.coe.int\/en\/web\/interculturalcities\/-\/initiatives-of-the-city-of-montreal-during-the-covid-19-crisis]"},{"key":"996_CR36","unstructured":"Urban Health Research Initiative. Drug situation in Vancouver. Vancouver, BC: British Columbia Centre for Excellence in HIV\/AIDS; 2013. [https:\/\/www.bccsu.ca\/wp-content\/uploads\/2016\/08\/dsiv2013.pdf]"},{"issue":"4","key":"996_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jinf.2005.07.008","volume":"52","author":"E Wood","year":"2006","unstructured":"Wood E, Kerr T, Palepu A, Zhang R, Strathdee SA, Tyndall MW, et al. Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users. J Infect. 2006;52(4):233\u20136.","journal-title":"J Infect"},{"key":"996_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-3-18","volume":"3","author":"E Wood","year":"2006","unstructured":"Wood E, Stoltz J, Montaner J, Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 2006;3:18.","journal-title":"Harm Reduct J"},{"key":"996_CR39","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11524-021-00547-w","volume":"98","author":"A Scheim","year":"2021","unstructured":"Scheim A, Sniderman R, Wang R, Bouck Z, McLean E, Mason K, et al. The Ontario Integrated Supervised Injection Services cohort study of people who inject drugs in Toronto, Canada (OiSIS-Toronto): cohort profile. J Urb Health. 2021;98:538\u201350.","journal-title":"J Urb Health"},{"issue":"8","key":"996_CR40","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/add.14632","volume":"114","author":"E Fortier","year":"2019","unstructured":"Fortier E, Artenie AA, Zang G, Jutras-Aswad D, Roy \u00c9, Grebely J, et al. Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montr\u00e9al, Canada. Addiction (Abingdon England). 2019;114(8):1495\u2013503.","journal-title":"Addiction (Abingdon England)"},{"key":"996_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/1471-2458-10-295","volume":"10","author":"HA Korteweg","year":"2010","unstructured":"Korteweg HA, van Bokhoven I, Yzermans CJ, Grievink L. Rapid Health and needs assessments after disasters: a systematic review. BMC Public Health. 2010;10:295.","journal-title":"BMC Public Health"},{"key":"996_CR42","unstructured":"Government of Canada. Canada Emergency Response Benefit (CERB); 2022. [https:\/\/www.canada.ca\/en\/revenue-agency\/services\/benefits\/apply-for-cerb-with-cra.html]"},{"key":"996_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugpo.2017.12.011","volume":"53","author":"B Wallace","year":"2018","unstructured":"Wallace B, Barber K, Pauly BB. Sheltering risks: implementation of harm reduction in homeless shelters during an overdose emergency. Int J Drug Policy. 2018;53:83\u20139.","journal-title":"Int J Drug Policy"},{"key":"996_CR44","doi-asserted-by":"publisher","first-page":"109633","DOI":"10.1016\/j.drugalcdep.2022.109633","volume":"241","author":"S Moallef","year":"2022","unstructured":"Moallef S, Genberg BL, Hayashi K, Mehta SH, Kirk GD, Choi J, et al. Day-to-day impact of COVID-19 and other factors associated with risk of nonfatal overdose among people who use unregulated drugs in five cities in the United States and Canada. Drug Alcohol Depend. 2022;241:109633.","journal-title":"Drug Alcohol Depend"},{"key":"996_CR45","doi-asserted-by":"crossref","unstructured":"Mitra S, Choi J, van Draanen J, Kerr T, Gilbert M, Hayashi K et al. Socioeconomic marginalization and risk of overdose in a community-recruited cohort of people who use drugs: a longitudinal analysis. Int J Drug Policy. 2023; 1873\u20134758 (Electronic).","DOI":"10.1016\/j.drugpo.2023.104117"},{"issue":"1","key":"996_CR46","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1186\/s12889-023-15929-9","volume":"23","author":"A Swaich","year":"2023","unstructured":"Swaich A, Richardson L, Cui Z, DeBeck K, Milloy MJ, Kerr T, et al. Experiences of violence during the COVID-19 pandemic among people who use drugs in a Canadian setting: a gender-based cross-sectional study. BMC Public Health. 2023;23(1):1020.","journal-title":"BMC Public Health"},{"issue":"7","key":"996_CR47","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/add.15862","volume":"117","author":"T Gomes","year":"2022","unstructured":"Gomes T, McCormack D, Bozinoff N, Tadrous M, Antoniou T, Munro C, et al. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. Addiction (Abingdon England). 2022;117(7):1972\u201381.","journal-title":"Addiction (Abingdon England)"},{"key":"996_CR48","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.drugpo.2022.103680","volume":"104","author":"Z Bouck","year":"2022","unstructured":"Bouck Z, Scheim AI, Gomes T, Ling V, Caudarella A, Werb D. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104:103680.","journal-title":"Int J Drug Policy"},{"key":"996_CR49","unstructured":"Government of Canada. Subsection. 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada; 2021. [https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/policy-regulations\/policy-documents\/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic.html]"},{"key":"996_CR50","volume-title":"Telemedicine Support for Addiction Services: National Rapid Guidance Document","author":"J Bruneau","year":"2020","unstructured":"Bruneau J, Rehm J, Wild TC, Wood E, Sako A, Swansburg J, Lam A. Telemedicine Support for Addiction Services: National Rapid Guidance Document. Montreal: Canadian Research Initiative in Susbtance Misuse; 2020. [https:\/\/crism.ca\/wp-content\/uploads\/2020\/05\/CRISM-National-Rapid-Guidance-Telemedicine-V1.pdf]"},{"key":"996_CR51","doi-asserted-by":"publisher","first-page":"103894","DOI":"10.1016\/j.drugpo.2022.103894","volume":"110","author":"C Zolopa","year":"2022","unstructured":"Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, et al. Changes in supervised consumption site use and emergency interventions in Montr\u00e9al, Canada in the first twelve months of the COVID-19 pandemic: an interrupted time series study. Int J Drug Policy. 2022;110:103894.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"996_CR52","doi-asserted-by":"publisher","first-page":"e1002964","DOI":"10.1371\/journal.pmed.1002964","volume":"16","author":"MC Kennedy","year":"2019","unstructured":"Kennedy MC, Hayashi K, Milloy MJ, Wood E, Kerr T. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: a cohort study. PLoS Med. 2019;16(11):e1002964.","journal-title":"PLoS Med"},{"issue":"9775","key":"996_CR53","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","volume":"377","author":"BD Marshall","year":"2011","unstructured":"Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study. Lancet (London England). 2011;377(9775):1429\u201337.","journal-title":"Lancet (London England)"},{"key":"996_CR54","unstructured":"Government of Canada. Opioid- and stimulant-related harms in Canada; 2022. [https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/]"},{"key":"996_CR55","unstructured":"City of Vancouver. Downtown Eastside; 2022. [https:\/\/vancouver.ca\/news-calendar\/downtown-eastside.aspx]"},{"issue":"2","key":"996_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drugpo.2005.12.007","volume":"17","author":"E Wood","year":"2006","unstructured":"Wood E, Kerr T. What do you do when you hit rock bottom? Responding to drugs in the city of Vancouver. Int J drug Policy. 2006;17(2):55\u201360.","journal-title":"Int J drug Policy"},{"key":"996_CR57","doi-asserted-by":"crossref","unstructured":"Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017(1477\u20137517 (Electronic)).","DOI":"10.1186\/s12954-017-0154-1"},{"key":"996_CR58","unstructured":"United Nations. UN Research Roadmap for the COVID-19 Recovery - Leveraging the Power of Science for a More Equitable, Resilient and Sustainable Future; 2020. [https:\/\/www.un.org\/en\/coronavirus\/communication-resources\/un-research-roadmap-covid-19-recovery]"},{"key":"996_CR59","doi-asserted-by":"crossref","first-page":"205520762110284","DOI":"10.1177\/20552076211028404","volume":"7","author":"M Perri","year":"2021","unstructured":"Perri M, Guta A, Gagnon M, Bonn M, Leece P, Bayoumi AM, et al. Developing a digital health strategy for people who use drugs: lessons from COVID-19. Digit Health. 2021;7:20552076211028404.","journal-title":"Digit Health"},{"key":"996_CR60","unstructured":"Gomes T, Murray R, Kolla G, Leece P, Kitchen S, Campbell T, Besharah J, Cahill T, Garg R, Iacono A, Munro C, Nunez E, Robertson L, Shearer D, Singh S, Toner L, Watford J. on behalf of the Ontario Drug Policy Research Network, Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). Patterns of medication and healthcare use among people who died of an opioid-related toxicity during the COVID-19 pandemic in Ontario. Toronto, ON: Ontario Drug Policy Research Network; 2022. [https:\/\/odprn.ca\/wp-content\/uploads\/2022\/01\/Opioid-Related-Toxicity-Deaths-and-Healthcare-Use-Report.pdf]"},{"key":"996_CR61","doi-asserted-by":"publisher","first-page":"102840","DOI":"10.1016\/j.drugpo.2020.102840","volume":"83","author":"H Reddon","year":"2020","unstructured":"Reddon H, Kerr T, Milloy MJ. Ranking evidence in substance use and addiction. Int J Drug Policy. 2020;83:102840.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"996_CR62","doi-asserted-by":"publisher","first-page":"174","DOI":"10.17269\/s41997-018-0058-1","volume":"109","author":"AI Scheim","year":"2018","unstructured":"Scheim AI, Bardwell G, Rachlis B, Mitra S, Kerr T. Syringe sharing among people who inject drugs in London, Canada. Can J Public Health. 2018;109(2):174\u201382.","journal-title":"Can J Public Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00996-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00996-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00996-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T01:04:40Z","timestamp":1715821480000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00996-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00996-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M-J.S.M. is the Canopy Growth professor of cannabis science at the University of British Columbia, a position established through arms\u2019 length gifts to the university from Canopy Growth, a licensed producer of cannabis, and the Government of British Columbia\u2019s Ministry of Mental Health and Addictions. He has no financial relationship to the cannabis industry. D.W. has a financial interest in a private company, DoseCheck Technologies Limited, that is developing a mobile drug checking technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}